Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Saturday, February 16, 2013

Incident anemia improved response to peginterferon, ribavirin, boceprevir in HCV patients

Patients with chronic hepatitis C who developed anemia during treatment with pegylated interferon alfa-2b, ribavirin and boceprevir were more likely to experience sustained virologic response in a recent study.
As part of the Serine Protease Inhibitor Therapy 2 (SPRINT-2) Trial, 1,097 patients with chronic HCV genotype 1 randomly were assigned either peginterferon and ribavirin (PegIFN/RBV) with placebo or 800 mg boceprevir (BOC) three times a day for 44 weeks or response-guided PegIFN/RBV with BOC, following 4 weeks of lead-in therapy with PegIFN/RBV. Nearly all patients (n=1,080) had hemoglobin (Hb) levels measured during the study. Anemia (Hb below 10 g/dL) was managed with erythropoietin and/or RBV dose reduction.

Read more....

No comments:

Post a Comment